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Abstract
Background: Contrast echocardiography is a precise tool for the non-invasive assessment of
myocardial function and perfusion. Side effects of contrast echocardiography resulting from
contrast-agent induced myocardial micro-lesions have been found in animals. The goal of this study
is to measure markers of myocardial necrosis, inflammation and oxidative stress in humans to
evaluate potential side-effects of contrast echocardiography.
Methods: 20 patients who underwent contrast echocardiography with Optison as the contrast
medium were investigated. To evaluate myocardial micro-necrosis, inflammation and oxidative
stress, cardiac troponin I (cTnI), tumor necrosis factor-α (TNF-α), interleukin (IL)-6, -8 and
thiobarbituric acid reactive substances (TBARS) were measured at baseline and at 2, 4, 8 and 24
hours after contrast echocardiography.
Results: At baseline, 50% of the patients had cTnI and TBARS values outside the reference range.
TNF-α, IL-6, IL-8 levels were within the reference range. Patients with cTnI above the RR clustered
to significantly higher levels of TNF-α and IL-6. After contrast echocardiography, no statistically
significant increase of cTnI, cytokines and TBARS was found. However, for nearly 50% of the
patients, the intra-individual cTnI kinetics crossed the critical difference (threefold of methodical
variation) which indicates a marker increase. This was neither predicted by the baseline levels of
the cytokines nor the markers of oxidative stress.
Conclusion: There are no clinically relevant increases in serum markers for micro-necrosis,
inflammation and oxidative stress in humans after contrast echocardiography. Future studies have
to address whether cTnI increase in some patients represent a subset with increased risk for side
effects after contrast echocardiography.
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Background
Contrast echocardiography is a precise and study-proven
tool for the non-invasive assessment of left ventricular
systolic function, myocardial perfusion, endocardial bor-
der detection and coronary flow reserve [1,2].
Myocardial trauma, e.g. occlusion of a coronary artery
during angioplasty, can potentially stimulate inflamma-
tory processes with subsequent activation and infiltration
of inflammatory cells in the myocardium. This can induce
the release of cytokines and reactive oxygen species [3].
Microbubbles in their use as ultrasound contrast agents,
which are destroyed by ultrasound, potentially also pose
a risk for myocardial micro-lesions. This was demon-
strated by in vitro and in vivo studies [4-7]. Therefore, in
addition to markers of myocardial necrosis (cTnI), the
measurement of markers for inflammation (TNF-α, IL-6,
IL-8) and oxidative stress (TBARS) in peripheral blood is
an appropriate tool to evaluate myocardial injury in
humans undergoing contrast echocardiography.
These markers are not specific for myocardial damage but
the degree of oxidative stress is correlated to the extent and
progression of myocardial damage. [8-11]. It has been
demonstrated in previous studies that levels of thiobarbi-
turic acid reactive substances (TBARS) are elevated in
patients with cardiovascular disease [12]. These patients
might have a higher individual risk to develop side-effects
from contrast myocardial echocardiography.
In a former study, we analyzed markers for myocardial
necrosis (myoglobin, cardiac troponin I, creatine kinase
MB activity and mass) in patients undergoing contrast
echocardiography. None of the markers crossed the cut-
offs  generally accepted to indicate myocardial necrosis
[13]. Possibly, one reason to these negative findings is that
the cut-off values deducted from ROC-curves which were
used at that time were too high for the detection of micro-
lesions after contrast echocardiography. Based on strongly
improved assay performance, it is now generally agreed
that the elevation of cTnI without crossing the former cut-
off is indicative of myocardial micro-necrosis [14]. Conse-
quently, myocardial infarction without clinical symptoms
– also termed "minor myocardial infarction" – is now re-
defined as a troponin increase above the 99% percentile
of the reference population or a troponin increase of more
than the level that can be measured with an imprecision
of = 10%, respectively [15-17].
Furthermore, there is increasing evidence that a low level
troponin increases are pathologically relevant. Specifi-
cally, cTnI values below the ROC cut-off are clearly associ-
ated with mild and subclinical myocardial damage [18].
In this study, we performed additional measurements on
the serum samples of the former study. cTnI concentra-
tions were measured at baseline and at 2, 4, 8 and 24
hours after contrast echocardiography. Furthermore, we
measured the markers of inflammation and oxidative
stress (TNF-α, IL-6, IL-8 and TBARS).
Materials and methods
20 consecutive patients with a clinical indication for con-
trast echocardiography were included in this study. The
indications for contrast echocardiography are listed in
table 1. The patients were clinically stable, older than 18
years of age and had signed an informed consent. Exclu-
sion criteria included acute coronary syndrome, hemody-
namic instability and cardiogenic shock. The study
protocol was approved by the ethics committee of the
Charité University Hospital. The venous blood sampling
was performed immediately before (baseline) and 2, 4, 8
and 24 hours after contrast echocardiography. Due to lim-
ited availability of the plasma samples, in only 16 of the
20 patients all cytokines (TNF-α, IL-6, IL-8) could be
measured.
Table 1: Baseline characteristics of the patients and indication for contrast echocardiography
Diagnosis n Contrast imaging indication
Ischemic n = 6
Coronary heart disease 6 Endocardial border detection / myocardial perfusion
Non-ischemic n = 14
Dilated cardiomyopathy 6 Endocardial border detection
Aortic valve replacement 2 Doppler flow enhancement / Endocardial border detection
Myocarditis 1 Endocardial border detection
Chronic obstructive lung disease 1 Endocardial border detection
Hypertensive heart disease 2 Endocardial border detection
Hypertrophic obstructive cardiomyopathy 2 Endocardial border detection / Doppler flow enhancement
Total 20Cardiovascular Ultrasound 2005, 3:21 http://www.cardiovascularultrasound.com/content/3/1/21
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The critical difference indicating a marker increase after
echocardiography was calculated based on the data for the
within-run variation. There is general agreement that two
values measured within-run are significantly different (p <
0.05) if the difference between the values is greater than
the three-fold of the within-run variation of the method.
Contrast echocardiography was performed with the Vivid
Five System (GE Vingmed Ultrasound, Horten, Norway).
Optison (perfluoro-propane-filled albumin micro-
spheres, Mallinckrodt, St. Louis, Mo, USA) was used as the
contrast medium. 20 ml of contrast microbubble solution
(3 ml Optison and 17 ml 0.9% saline solution) were
infused manually over three minutes into a peripheral
vein followed by a saline flush. Contrast echo was per-
formed 5 minutes after the beginning of the application of
the contrast solution.
Cardiac troponin I was measured with the heterogeneous
immunoassay module cardiac troponin-I flex™ reagent
cartridge for Dimension (Date Behring, Marburg, Ger-
many). For this assay, the lowest limit of detection (LoD)
is 0.04 µg/l. The 99%-percentile of the reference group is
0.07 µg/l. In the range below the ROC cut off (0.6 µg/l),
the analytical variation is 10% at a cTnI level of 0.24 µg/l
and nearly 20 % at the 99 % percentile [14].
For TNF-α, IL-6 and IL-8, IMMULITE immunoassays
obtained from DPC Biermann GmbH (Bad Nauheim,
Germany) were used. According to the manufacturer
information, reference ranges (95% percentile) and their
analytical variation for TNF-α, IL-6 and IL-8 are 12% at
8.1 ng/l, 7% at 9.7 ng/l and 3.5% at 62 ng/l respectively.
The LoD and the analytical variation at this level are 18%
at 4 ng/l; 10% at 2 ng/l and 6% at 5 ng/l.
TBARS was measured according to TAKEDA et al. [19]. To
avoid unspecific TBARS changes caused by in vitro oxida-
tion and to guarantee high precision in the analytical pro-
cedures, adequate conditions for sampling, storage and
measurement were ascertained in pre-study experiments
[20]. Therefore, samples for TBARS were immediately fro-
zen after sampling, stored in liquid nitrogen until meas-
urement and analysed in parallel for high precision.
Under these circumstances, the within-run variation was
3.8 %. There is no standardized test for TBARS, so that
measurements have to be compared with the laboratory
specific reference range. Based on former investigations,
the reference group of 20 age-matched healthy controls
had a mean value of 3.82 ± 0.51 µmol/l (min 2.62 – max
5.06 µmol/l). The 95%-percentile of the reference group is
4.79 µmol/l.
Statistical Analysis
Data are expressed as mean ± SD. Statistical analysis was
performed with the SPSS 12 software package (SPSS; Chi-
cago, Ill, USA). Using bootstrapping simulation, the U-
test of Mann-Whitney for group comparison and the Wil-
coxon test for comparison of paired values (pre-study
value vs. maximum value following contrast echocardiog-
raphy) were used. In the figures, the measurements below
the LoD are displayed by the values that correspond to
half of the LoD.
Results
A) Marker levels at baseline
cTnI
7 of the 20 patients had baseline cTnI levels below the
LoD (0.04 ug/l). 3 patients had a cTnI level between the
LoD and the 99%-percentile of the reference population
(≤ 0.07µg/l). Altogether, 10 patients were within the refer-
ence range. The other 10 patients had baseline cTnI levels
above the reference range: 8 patients with values between
the 99%-percentile and the ROC cut-off of 0.6 µg/l and 2
patients with values which were even above the ROC cut-
off. (see table 2, figure 1). As shown in figure 2, one
patient had a much higher baseline cTnI level (1.99µg/l)
than all the others. The patient was diagnosed with
chronic dilated cardiomyopathy and intermittent ven-
tricular bigeminus and couplets. In contrast to elevated
levels of cTnI and TBARS, he had normal levels of the
other markers at baseline.
Cytokines
For TNF-α (reference range ≤ 8.1 ng/l), 3 of the 16 patients
had baseline values above the reference range. Two
patients belonged to the group with cTnI in the reference
range, one to the group with cTnI above the reference
range.
However, comparing all baseline TNF-α levels to the cTnI
levels (inside or outside the reference range), TNF-α was
significantly lower in the patient group with cTnI in the
reference range (3.8 ± 2.6 vs. 9.4 ± 5.7 ng/l ; 95 %
Table 2: Classification of patients according to baseline levels of 
cTnI, TNF-α, IL-6, IL-8 and TBARS with respect to inside or 





cTnI (n = 20) 10 10
TNF-α (n = 16) 11 3
IL-6 (n = 16) 14 2
IL-8 (n = 16) 16 0
TBARS (n = 20) 6 14Cardiovascular Ultrasound 2005, 3:21 http://www.cardiovascularultrasound.com/content/3/1/21
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confidence interval of the p value 0.030 – 0.037) than the
patients with cTnI above the reference range. The correla-
tion of cTn-I and TNF-α is also documented by the regres-
sion analysis (r = 0.57; p = 0.043).
For IL-6 (reference range of ≤ 9.7 ng/l), two patients both
from the cTnI group outside of the reference range had IL-
6 values outside of the reference range. In analogy to the
TNF-α levels, there was a significantly higher IL-6 level in
the patient group outside of the cTnI reference range com-
pared with that inside (vs. 2.0 ± 1.0 vs.13.3 ± 16.9 ng/l; 95
% confidence interval of the P value 0.009 to 0.014). The
linear regression of baseline IL-6 and cTnI was r = 0.68 (p
= 0.01). A significant correlation of baseline TNF-α and
IL-6 could be calculated (r = 0.58; p < 0.05).
For IL-8, the baseline values of all patients were all within
the reference range. There was no significant difference in
IL-8 values between the patient groups inside and outside
of the cTnI reference interval (13.8 ± 22.6 vs. 10.0 ± 7.2
ng/l).
Oxidative stress
Based on the calculated reference range (95%-percentile)
the TBARS level of 6 of the patients was inside the refer-
ence range, while in 14 patients it was outside of the ref-
erence range at baseline. TBARS levels were significantly
higher in the patient group compared to the healthy con-
trols: mean 5.82 ± 1.30 µmol/l (min 4.18 µmol/l, max
9.23  µmol/l, 95 % confidence interval of the P value:
0.001 to 0.0001). However, no significantly different
Boxplot analysis of the baseline concentration of TNF-α, IL-6, IL-8 and TBARS in the plasma of patients with plasma cTnI inside  or outside of the reference range Figure 1
Boxplot analysis of the baseline concentration of TNF-α, IL-6, IL-8 and TBARS in the plasma of patients with plasma cTnI inside 
or outside of the reference range. Despite the significant differences in the mean values of TNF-α and IL-6 at baseline, the 
intra-individual changes were not statistically significant.Cardiovascular Ultrasound 2005, 3:21 http://www.cardiovascularultrasound.com/content/3/1/21
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TBARS levels (5.98 ± 1.65 vs 5.61+0.81 µmol/l) were
found in the cTnI groups inside or outside the reference
range. There was no significant correlation of baseline
TBARS to cTnI, TNF-α and IL-6, however, the TBARS cor-
related significantly to the baseline IL-8 (r = 0.82; p <
0.01).
Overall, if patients were classified based on their underly-
ing heart disease in "ischemic" (n = 6) and "non-
ischemic" (n = 14), no significantly different pre-study
levels for all parameters are present.
B) Marker levels after contrast echocardiography
cTnI
As shown in figure 1 the mean cTnI levels were 0.26 ± 0.47
ng/l (baseline), 0.47 ± 1.37 ng/l (2 hours), 0.24 ± 0.48 ng/
l (4 hours), 0.24 ± 0.45 ng/l (8 hours), 0.18 ± 0.33 (24
hours). Based on the definition of marker increase as
described in material and methods, the intra-individual
kinetics showed a cTnI increase for 9 patients after con-
trast echocardiography at one or more time points com-
pared to baseline (figure 2). The strongest increase (to
6.35 µg/l) was found for the patient with the highest base-
line cTnI. This high value was only found 2 hours after
Increase of cTnI after contrast echocardiography: Baseline  value and the maximum value within 24 hours after contrast  echocardiography Figure 2
Increase of cTnI after contrast echocardiography: Baseline 
value and the maximum value within 24 hours after contrast 
echocardiography. The dotted lines indicate patients with no 
significant increase. The black lines represent patients with an 
increase greater than the three-fold of the within-run variation 
of the method.
Time kinetics of cTnI, TNF-α, IL-6, IL-8 and TBARS levels at baseline and at 2, 4, 8 24 hours and maximum value after contrast  echocardiography Figure 3
Time kinetics of cTnI, TNF-α, IL-6, IL-8 and TBARS levels at baseline and at 2, 4, 8 24 hours and maximum value after contrast 
echocardiography.Cardiovascular Ultrasound 2005, 3:21 http://www.cardiovascularultrasound.com/content/3/1/21
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contrast echocardiography and returned to baseline there-
after. This patient had no significant changes of the
cytokine and TBARS levels. Despite a cTnI increase in
some patients, statistical analysis using the Wilcoxon test
for comparison of paired values did not reveal a signifi-
cant increase for the whole group of patients (figure 3).
There was no predictive power of baseline cTnI levels for
an increase after contrast echocardiography. In the group
with baseline cTnI within the reference range, we found
an increase based on our definition in 5 of the 10 patients.
In the group with baseline cTnI above the reference range,
the increase was seen in 4 of the 10 patients.
Neither the etiology of the heart disease (ischemic and
non-ischemic) nor the baseline cTnI level predicted an
increase in cTnI.
TNF-α and Cytokines
In the case of TNF-α and cytokines, the critical difference
was crossed 24 hours after contrast echocardiography for
TNF-α in 3, for IL-6 in 6 and for IL-8 in 7 of the analyzed
patients. The marker increase was neither related to the
baseline cTnI nor to the ischemic or non-ischemic back-
ground. The correlation of cytokine and cTnI increase was
not statistically significant.
Oxidative stress
The oxidative stress marker TBARS exceeded the critical
difference after contrast echocardiography in 7 patients.
The increase of TBARS was neither related to the baseline
cTnI nor to the ischemic or non-ischemic background of
the underlying myocardial pathology of the patient.
Discussion
This study was designed to investigate safety of contrast
echocardiography in humans. By determination of serum
markers for myocardial necrosis, inflammation and oxi-
dative stress, no statistically significant side-effects could
be detected. In the most of the patients, the baseline
marker levels were within or near to the reference range
and there were no sustained increases 24 hours after con-
trast echocardiography.
As marker for myocardial necrosis, cTnI was chosen
because the analytical sensitivity of the test has improved
and it is now accepted as an indicator of myocardial
micro-necrosis. Furthermore, there is increasing evidence
that cTnI can indicate myocardial damage that is not asso-
ciated with necrosis [21-24].
To examine inflammatory activation after contrast
echocardiography, TNF-α and IL-6 and IL-8 were ana-
lyzed. These markers are not specific for a myocardial
inflammatory response, but a marker increase with tem-
poral association to contrast echocardiography more
likely results from the proposed effects of the contrast
agent on the heart than from systemic inflammation by
other causes [25].
TBARS, a metabolite and end product of lipid peroxida-
tion, is a more static and global parameter. TBARS is,
despite the lack in standardization, currently the most fre-
quently used marker to quantify oxidative stress in clinical
studies. It was measured in several studies in patients with
heart diseases and increased oxidative stress [12,26]. The
patients in our study had significantly higher baseline
TBARS levels than the control group of age-matched
healthy subjects. This is in agreement with the data dem-
onstrating that the induction of oxidative stress is a seque-
lae in the pathogenesis of heart diseases.
Our results after contrast echocardiograph in humans are
be in agreement with a recently published study. A new
second-generation myocardial contrast agent (LK565) has
been evaluated in healthy individuals undergoing con-
trast echocardiography. Neither an increase in TNF-α
secretion, nor antibody development and activation of
leukocyte surface markers was induced by the procedure
[27]. However, these results found in healthy subjects can-
not be simply transferred to studies such ours since
patients with heart disease could develop side-effects
which are more pronounced in quality and quantity.
Consequently and in critical view of our study results, we
hesitate to negate a potential myocardial damage after
contrast echocardiography. An intra-individual increase
of cTnI above the pre-determined limit was seen in nearly
half of the patients. Furthermore, IL-6 and IL-8 increased
after contrast echocardiography based on the pre-defined
limit in nearly half of the patients analysed for cytokines.
The increases of cTnI, IL-6 and IL-8 were not correlated to
a particular group of patients. Further larger studies have
to clarify whether subgroups of patients are prone to myo-
cardial damage after contrast echocardiography. In
present study, we cannot exclude that the findings in
some of our patients resulted from such a subset enrolled
in our patient cohort. Due to the sample size we were not
able to clearly define subgroups. In our view, patients with
cTnI or TBARS above the reference range at baseline could
form such a subgroup more susceptible to side- effects.
Possibly, the one patient suffering from dilated cardiomy-
opathy and ventricular arrhythmia who had the highest
baseline and largest increase in cTnI levels after contrast
echocardiography could belong to such a subgroup. High
troponin levels are found in patients with stable heart fail-
ure without an indication for myocardial ischemia [20-
22,28]. Furthermore, patients with tachycardia can have
persistently high troponin levels [29] which might explainCardiovascular Ultrasound 2005, 3:21 http://www.cardiovascularultrasound.com/content/3/1/21
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the elevated baseline level of cTnI in our patient affected
by intermittent ventricular bigeminus and ventricular
couplets. However, the cTnI increase after contrast
echocardiography in this patient was neither reflected by
a rise in cytokines nor in oxidative stress and was not
accompanied by clinical signs and symptoms of myocar-
dial ischemia. Therefore, it is unclear whether this cTnI
increase is linked to the contrast echocardiography proce-
dure alone or if it primarily reflects the underlying heart
disease.
We have found a significant correlation of the baseline
levels of cTnI, TNF-α and IL6. This is in accordance with
the findings of [30], who found an association of tro-
ponin and cytokine levels in heart disease.
Limitations of this study include the low number of
patients, the lack of a control group and the use of just one
contrast agent. Increasing the number of patients studied
would facilitate the identification of patients who are
more sensitive to the side-effects of contrast echocardiog-
raphy. Controls in future studies would have to receive
contrast agent only without echocardiography. We cannot
draw comparisons between the effects of different contrast
agents because only Optison was used in this study.
In summary, there is no conclusive evidence for the induc-
tion of myocardial micro-necrosis, inflammation and oxi-
dative stress by contrast echocardiography. The baseline
cTnI levels do not correlate to the oxidative stress and
inflammation markers within 24 hours after contrast
echocardiography. In some of the patients however, cTnI
levels increase slightly after contrast echocardiography.
These patients may belong to a subgroup more prone to
side effects of contrast echocardiography than others.
Hence, this study – although limited in size – suggests that
contrast echocardiography does not induce oxidative
stress and inflammation.
Abbreviations
TNF-α Tumor necrosis factor alpha
TBARS thiobarbituric acid reactive substances
IL Interleukin
ROC Reviever operating characteristic curve
cTnI cardiac Troponin I
LoD lowest limit of detection
MI myocardial infarction
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